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Although patients with psoriasis and transplant recipients are older, burdened by metabolic and cardiovascular comorbidities, and
above all, immunosuppressed, there is no early
signal of an increased hospitalization or death
from COVID-19. We acknowledge that patients
on biologics or immunosuppressive drugs may
have self-isolated more effectively and focused
on improved hygiene, thus limiting their own
infection risk.
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Recommendations for phototherapy
during the COVID-19 pandemic
To the Editor: The COVID-19 pandemic has resulted
in the closure of many phototherapy units in the
United States and around the world, especially in
areas hard hit by the pandemic, with difficulty in
maintaining social distancing being a driving factor.
Currently, there is no guidance on managing a
phototherapy service or resuming the service during
this pandemic.
Because COVID-19 risk varies with disease prevalence and because disease prevalence varies in
different locations, the decision to continue or
resume phototherapy operations needs to be made
based on local public health recommendations, and
for medical center-based units, in consultation with
the institution’s infection control unit. To provide
information for clinicians, the following recommendations are based on the consensus opinion of
members of the dermatology expert committee of
the Light Treatment Effectiveness (LITE) study, a
pragmatic trial of home vs office narrowband ultraviolet (UV) B phototherapy in 1050 patients at
approximately 30 sites across the United States.1
The committee consists of dermatologists who have
long-standing expertise in the management of patients on phototherapy.
The principle that we use in developing the
recommendations is to balance risks and benefits
for patients and to optimize safety for staff.
Currently, the risk of spreading COVID-19 in a
shared phototherapy setting is unknown. The
germicidal property of UV light may be helpful in
limiting COVID-19 in the phototherapy unit. UVC
has been used for decontamination of N95 filtering
face piece respirators during the pandemic.2 On the
basis of extrapolation of 254-nm UVC virus inactivation data using viruses other than severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2),
solar radiation, including UVB and UVA, has been
estimated to also have virucidal effect.3
Office phototherapy is generally not the only
option; therefore, risks and benefits of options,
including home phototherapy and judicial exposure
to natural sunlight, should be weighed. For sites
providing a targeted phototherapy service (excimer
laser or light), for the safety of the staff, treatment of
facial lesions should be minimized, or if possible,
avoided.
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Once a decision to continue or to resume phototherapy service has been made, the following
recommendations are made:
Consider to have all patients:
 Be screened for symptoms, based on local
guidelines, before entering the unit, understanding that those with symptoms might be denied
treatment;
 Attend the phototherapy appointment alone (ie,
family members, friends, caregivers should not
enter the medical facility). If the patient is a
minor, 1 guardian is allowed to accompany the
patient. Screening, wearing a homemade mask,
applying hand sanitizer, and practicing social
distancing would be required of the guardian;
 Wear a homemade cotton mask, with the exception during the total body phototherapy treatment;
 Apply hand sanitizer upon entering and leaving
the unit;
 Be provided with their individual goggles (if the
face is exposed during phototherapy) that can be
stored in the unit in an individualized plastic bag.
Patients should clean the goggles according to
manufacturer’s instructions thoroughly with disinfecting wipes before putting it in the bag;
 Be given a bag to store their clothes when they
disrobe, and bag is discarded at end of treatment;
 Practice social distancing.
Staff should consider to:
 Schedule patients not more than every
30 minutes;
 Arrange waiting area with seats 6 feet apart;
 Wear a mask;
 Apply hand sanitizer before and after each patient encounter;
 Avoid turning on the fan of the phototherapy
unit if possible; if need be, treatment can be
fractionated to avoid excessive heat build-up in
the unit;
 Disinfect high-touch surfaces in the changing
area after each patient;
 Disinfect high-touch area of the phototherapy
equipment in between patients.
Once the public health authority has given the
permission to resume unrestricted daily activity,
practice performed before the pandemic can then
be done.
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Clinical considerations for
managing dermatology patients on
systemic immunosuppressive or
biologic therapy, or both, during the
COVID-19 pandemic
To the Editor: Concern exists about COVID-19 in
patients treated with systemic immunosuppressive or biologic therapy, or both.1,2 However,
there are no data on the effects of COVID-19
infection in this population.1,3 We examined
randomized controlled trials (RCTs), systematic
reviews, and meta-analyses, focusing on RCTs for
dermatologic conditions and respiratory infections where available.
The results are presented in Table I, and a detailed
discussion is available in the Supplemental materials
(via Mendeley at https://doi.org/10.17632/bsjcgs
vvxw.2). Briefly, our findings suggest that upper
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